- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MRSN
Recent news which mentions MRSN
34 Stocks Moving In Monday's Mid-Day Session
April 18, 2022
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 16, 2022
From Benzinga
78 Biggest Movers From Friday
February 14, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 11, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 10, 2022
From Benzinga
60 Biggest Movers From Yesterday
February 10, 2022
From Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 09, 2022
From Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
February 09, 2022
From Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
From Benzinga
Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets
February 03, 2022
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 03, 2022
From Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
January 05, 2022
From Benzinga
Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B
November 30, 2021
Tickers
MRSN
From Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
November 10, 2021
Tickers
MRSN
From Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
October 08, 2021
Tickers
MRSN
From Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
From Benzinga
72 Biggest Movers From Yesterday
September 14, 2021
From Benzinga
45 Stocks Moving In Monday's Mid-Day Session
September 13, 2021
From Benzinga
60 Biggest Movers From Friday
September 13, 2021
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 10, 2021
From Benzinga
41 Stocks Moving In Friday's Mid-Day Session
September 10, 2021
From Benzinga
Why Are Mersana Therapeutics Shares Trading Lower On Friday?
September 10, 2021
Tickers
MRSN
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.